Treatment system for eye disease treatment, eye disease treatment method, and light module used therein

Abstract

The present invention relates to eye disease treatment and, more specifically, to a treatment system for eye disease treatment, an eye disease treatment method, and a light module used therein, which treat an eye disease by irradiating the eyes with light. The disclosed eye disease treatment system comprises: a main body module (10) in which a light module (100) for generating treatment light is provided, and which covers the eyes of a user so that the eyes of the user are irradiated with the light of the light module (100); and a wearing module (20) which is coupled to the main body module (10), and which extends to a side surface of the head of the user so as to be worn by the user.

Description

Treatment system for treating eye diseases, treatment method for eye diseases, and optical module used therefor

[0001] The present invention relates to the treatment of eye diseases, and more particularly, to a treatment system for treating eye diseases by irradiating light to the eye, a method for treating eye diseases, and an optical module used therefor.

[0002] As the average human lifespan increases, the number of age-related eye diseases is also rapidly increasing.

[0003] Common age-related eye diseases include presbyopia and cataracts, which occur with age, as well as dry eye, macular edema, macular degeneration, floaters, glaucoma, and nasolacrimal duct obstruction. Recently, the incidence of dry eye and macular degeneration, previously rare, has been on the rise.

[0004] Treatment methods for these eye diseases include intraocular injections, surgery, and eye drops. However, in the case of procedures or surgeries, there are problems that patients may feel reluctant to receive treatment due to side effects such as endophthalmitis and vitreous hemorrhage, and symptoms such as eye pain.

[0005] To solve these problems, eye treatment devices using light have been proposed, as in Patent Documents 1 and 2.

[0006] For reference, light with a wavelength of 435-485 nm is known to be effective in treating mild to moderate acne vulgaris. Furthermore, light with a wavelength of 435-485 nm is known to reduce skin inflammation, activate endogenous porphyrins, generate reactive oxygen species (ROS), destroy sebaceous glands, and kill P. acnes, the causative agent of acne. Furthermore, light with a wavelength of 435-485 nm is known to help suppress allergic diseases.

[0007] Light with a wavelength of 500-560 nm can be used to treat Bowen's disease, and when irradiated into the eye, it is known to help improve sleep, have psychological effects, and relieve pain. Furthermore, light with a wavelength of 500-560 nm is known to be effective in preventing glaucoma, a disease that can cause blindness. Glaucoma increases intraocular pressure, causing damage to the optic nerve, and green light is effective in lowering this intraocular pressure. Furthermore, light with a wavelength of 500-560 nm is known to have an effect on the nerves, alleviating pain from neurological disorders such as migraines.

[0008] Additionally, light with a wavelength of 590 nm is known to inhibit the production of VEGF, i.e., vascular endothelial growth factor. (See the paper, "590 nm LED Irradiation Improved Erythema through Inhibiting Angiogenesis of Human Microvascular Endothelial Cells and Ameliorated Pigmentation in Melasma," Department of Dermatology, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai 200040, China.)

[0009] Light with a wavelength of 610–760 nm, especially 680 nm, is known to help reduce inflammation and stimulate skin cells to produce collagen, a key component of skin healing. Furthermore, light with a wavelength of 610–760 nm, especially 680 nm, is known to affect the mitochondria of skin cells, helping them produce adenosine triphosphate, the cellular energy source. Consequently, light with a wavelength of 610–760 nm, especially 680 nm, produces skin-firming components, which improves wrinkles and aids energy production, improving skin tone. It can also be used to improve wound healing, promote hair growth, and treat psoriasis.

[0010] Light with wavelengths of UVA (320-400 nm), UVB (290-320 nm), and UVC (200-0 nm) can be used for various inflammatory diseases, including psoriasis, vitiligo, and atopic dermatitis.

[0011] Infrared light has several benefits, including pain relief and tissue repair. It is particularly useful for diabetics and is known to be effective in treating mild wounds due to impaired healing. Infrared light is also known to be useful in treating acne.

[0012] Green light can be used to improve sleep, relieve neuralgia, and treat glaucoma. Additionally, it is known to reduce aggressive behavior in people with mental illness, such as dementia, and improve depression.

[0013] Additionally, by stimulating the brain nerves through the eyes, it can help prevent neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

[0014] Red and blue light are known to suppress allergic diseases. They are also effective in treating allergic rhinitis, a condition that occurs inside the nose. Phototherapy can suppress the effector phase of allergic reactions, and intranasal phototherapy has been proven in clinical trials.

[0015] It is known that red light can be used to remove bacteria inside the mouth that cause periodontitis and promote the regeneration of gums, teeth, and bones after tooth extraction.

[0016] Allergic asthma can be suppressed by irradiating the inside of the throat with blue and red light.

[0017] It is known that red and blue light can be used to treat related diseases such as otitis externa by removing bacteria inside the ear, and can also be effective in treating wounds inside the ear.

[0018] Additionally, research has shown that stimulating brain nerves through light exposure inside the ear can prevent depression caused by seasonal affective disorder.

[0019] Infrared light can help treat hemorrhoids, a common anal condition. Applying infrared light to the affected area disrupts blood flow to the hemorrhoid, constricting the swollen veins. With consistent treatment, the hemorrhoids can disappear over time.

[0020] Exposure to red light and infrared rays is known to be effective in preventing diseases of the reproductive organs of menopausal women and in anti-aging.

[0021] Menopausal women experience a number of problems due to the decline in estrogen, including increased sensitivity to pain and increased vulnerability to additional diseases such as urinary incontinence due to muscle loss.

[0022] Red light stimulates the synthesis of collagen in the vaginal tissue and urethral submucosa, and promotes vasodilation, which can prevent urinary incontinence and genital-related aging phenomena.

[0023] Although there are no clear studies on the male genital area, it is known to be effective in treating fungal dermatitis, which mainly occurs on the skin around the genitals.

[0024] Red light exposure is known to enhance the healing effects of the skin and relieve pain and inflammation.

[0025] Additionally, blue light has the effect of eliminating staphylococci and bacteria, thus treating inflammation and rashes.

[0026] The eye treatment device of Patent Document 1 is characterized in that it treats the eyes by irradiating light to the eyes while the chin is supported on a chin rest and the eye area is in close contact with the interface surface.

[0027] However, the eye treatment device of Patent Document 1 has a configuration that irradiates light to the eyes while supporting the chin, which is not a problem for a short period of time, but has a problem that it is very inconvenient to irradiate the eyes for a relatively long period of time.

[0028] Patent Document 2 is a device for treating eye diseases by irradiating light to the eyes while worn on the head.

[0029] However, Patent Document 2 has the problem that the optical system structure is complex, making it difficult to manufacture, the head-mounted structure is inconvenient to wear, and the weight is large, making it uncomfortable to wear.

[0030] (Patent Document 1) KR 10-2021-0112072 A

[0031] (Patent Document 2) KR 10-2017-0058958 A

[0032] The purpose of the present invention is to provide a treatment system for treating eye diseases, a method for treating eye diseases, and an optical module used therein, which are easy to manufacture and convenient to use by simplifying the structure of an optical module for irradiating light to the eye, in consideration of the above-mentioned problems and trends.

[0033] The present invention has been created to achieve the above-described object of the present invention, and proposes a system for treating eye diseases, characterized by including a main body module (10) in which an optical module (100) for generating therapeutic light is installed and which covers the user's eyes so that the light of the optical module (100) is irradiated to the user's eyes; a wearable part (20) coupled to the main body module (10) and extended to the side of the user's head to be worn by the user; and a camera part (300) installed in the main body module (10) and which acquires an image of the user's eyes and tracks whether the light irradiated by the optical module (100) is stably irradiated to the user's eyes.

[0034] The above camera unit (300) may include a camera that recognizes at least one of infrared and visible light.

[0035] The above camera unit (300) may include an imaging unit (310) that acquires images of a pair of eyes of a user; an optical system (320) that induces light so that the imaging unit (310) can acquire images of a pair of eyes while the main body module (10) is worn by the user; and an image processing unit that processes the images acquired by the imaging unit (310).

[0036] The image processing unit may perform an eye object search step for searching for an eye object corresponding to an eye in a primary image acquired by the imaging unit (310); an eye object extraction step for extracting an eye object searched in the eye object search step; and a normal judgment step for analyzing the eye object extracted in the eye object extraction step to determine whether light irradiation is performed normally.

[0037] At least one of the above eye object search step, the eye object extraction step, and the normal judgment step can be performed by an artificial intelligence program.

[0038] At least one of the above eye object search step and the above normal judgment step can be performed by an artificial intelligence program.

[0039] The above treatment light may be a combination of light of multiple wavelengths.

[0040] When at least one of the above-described light sources is illuminated, the remaining light sources may be turned off.

[0041] When one of the above plurality of light sources is illuminated, the remaining light sources can be turned off.

[0042] The above plurality of investigation lights can be controlled to be turned on and off.

[0043] The above treatment light may include at least one of a first irradiation light having a blue wavelength; a second irradiation light having a green wavelength; a third irradiation light having a red wavelength; a fourth irradiation light having an ultraviolet wavelength; and a fifth irradiation light having an infrared wavelength.

[0044] As another aspect of the present invention, the present invention also discloses a system for treating eye diseases or an eye care system, characterized in that it includes a main body module (10) that covers the user's eyes so that a light module (100) that generates therapeutic light is installed and the light of the light module (100) is irradiated to the user's eyes; and a wearable part (20) that is coupled to the main body module (10) and extends to the side of the user's head and is worn by the user.

[0045] The above optical module (100) may include an LED module (100) including an LED substrate (112) having one or more LED elements (111) installed thereon; a light tube (120) to which the LED module (100) is coupled at one end; one or more lenses (141) installed in the light tube (120) and emitting light generated by the LED elements (111); a diffusion member (142) coupled to the light tube (120) to diffuse light; and a fixing member (130) coupled to the light tube (120) to fix the lens (141) and the diffusion member (142).

[0046] The present invention also discloses an optical module for an eye disease treatment system, characterized in that it includes an LED module (100) including an LED substrate (112) having one or more LED elements (111) installed thereon; a tube (120) to which the LED module (100) is coupled at one end; one or more lenses (141) installed in the tube (120) and emitting light generated by the LED elements (111); a diffusion member (142) coupled to the tube (120) and diffusing light; and a fixing member (130) coupled to the tube (120) and fixing the lens (141) and the diffusion member (142).

[0047] The present invention also provides an optical module (100), comprising: a light tube (120) having a hollow cylindrical structure; an LED module (110) including an LED substrate (112) coupled to one end of the light tube (120) and having a through-hole (113) corresponding to the hollow portion of the light tube (120) formed therein and having a plurality of LED elements (111) installed along a circumferential direction; a reflective member (151) coupled to one end of the light tube (120) and reflecting light generated from the plurality of LED elements (111) toward the hollow portion of the light tube (120); a spherical lens (152) installed in the light tube (120) and converging light reflected by the reflective member (151); Disclosed is an optical module of an eye disease treatment system, characterized in that it includes a guide lens (153) that guides light passing through the spherical lens (152) into a preset area.

[0048] The above LED element (111) may include at least one of a first LED element that irradiates light in a blue wavelength range; a second LED element that irradiates light in a green wavelength range; a third LED element that irradiates light in a red wavelength range; a fourth LED element that irradiates light in an ultraviolet wavelength range; and a fifth LED element that irradiates light in an infrared wavelength range.

[0049] The present invention also discloses an ophthalmic disease treatment system that generates three or more lights with different wavelengths and irradiates the light to the eyes of a user, the ophthalmic disease treatment system having the above configuration, and characterized in that the three or more lights include lights with a second wavelength of 680 nm ± 10 nm, a third wavelength of 780 nm ± 10 nm, and a fourth wavelength of 830 nm ± 10 nm.

[0050] The present invention also discloses a system for treating eye diseases, which includes an optical module (100) that generates three or more lights having different wavelengths and irradiates the light to the eyes of a user, wherein the three or more lights include lights having a second wavelength of 680 nm ± 10 nm, a third wavelength of 780 nm ± 10 nm, and a fourth wavelength of 830 nm ± 10 nm.

[0051] The sum of the irradiation intensities of the above 2 to 4 wavelengths of light is 35 to 40 mW / cm 2 It is desirable that.

[0052] The sum of the irradiation intensities of the light of the above 2 to 4 wavelengths is 37.8 mW / cm 2 It is more desirable that

[0053] The average value of the light irradiation intensity of the above second wavelength light is 12.3 mW / cm 2 , and the average value of the light irradiation intensity of the third wavelength light is 14.9 mW / cm 2 , and the average value of the light irradiation intensity of the fourth wavelength light is 10.6 mW / cm 2 It is desirable that.

[0054] The above 2 to 4 wavelengths of light can be irradiated to the user's eyes simultaneously.

[0055] The light of the above 2 to 4 wavelengths has an energy of 5.0 J / cm irradiated for 2 minutes. 2 It can be investigated in smaller detail.

[0056] The above three or more lights may additionally include light having a first wavelength of 590±10 nm.

[0057] The system for treating eye diseases according to the present invention can be used to treat or alleviate symptoms of at least one eye disease among dry eye, macular edema, and macular degeneration.

[0058] The treatment system for treating eye diseases, the method for treating eye diseases, and the optical module used therein according to the present invention have the advantage of being simple in structure and easy to manufacture, as an optical module corresponding to each eye of the user is installed to irradiate light to each eye.

[0059] In particular, the treatment system for treating eye diseases, the method for treating eye diseases, and the optical module used therein according to the present invention have the advantage of preventing excessive intensity light from being irradiated to the user's eyes by emitting light generated from an LED element using a light tube and transmitting the emitted light through a diffusion plate.

[0060] In addition, the treatment system for treating eye diseases, the method for treating eye diseases, and the optical module used therein according to the present invention have an advantage of being simple in overall structure and easy to manufacture, as an optical module corresponding to each eye of the user is installed and a reflective member is used for the optical path from the LED element to the user's eye when irradiating light to each eye.

[0061] According to another aspect of the present invention, the treatment system for treating eye diseases, the method for treating eye diseases, and the optical module used therein according to the present invention have the advantage of being able to treat and alleviate eye diseases such as dry eye, macular degeneration, and macular edema.

[0062] Figure 1 is a perspective view showing an example of a system for treating eye diseases according to the present invention.

[0063] Fig. 2a is a perspective view of the eye disease treatment system of Fig. 1 from a different angle, and Figs. 2b and 2c are cross-sectional views of the eye disease treatment system of Fig. 1 at different horizontal heights, respectively.

[0064] Figure 2d is a cross-sectional view taken in the DD direction in Figure 2c.

[0065] Figure 2e is an exploded perspective view showing a part of the camera unit illustrated in Figures 2c to 2d.

[0066] Fig. 3 is a perspective view showing the state in which the cover part is removed from the eye disease treatment system of Fig. 1.

[0067] Figure 4 is a front view of Figure 3, and Figure 5 is a back view of Figure 3.

[0068] Fig. 6a is a perspective view of an optical module of the ophthalmic disease treatment system of Fig. 1, and Fig. 6b is an exploded perspective view of an optical module of the ophthalmic disease treatment system of Fig. 1.

[0069] Fig. 7a is a cross-sectional view of the optical module of Fig. 6a, and Fig. 7b is a cross-sectional view according to a modified example of the optical module of Fig. 7a.

[0070] Fig. 8 is a front view of the LED module of the optical module of Fig. 6a.

[0071] Fig. 9 is a perspective view showing a state of wearing the eye disease treatment system illustrated in Fig. 2.

[0072] Fig. 10 is a cross-sectional view showing another example of an optical module of a system for treating eye diseases according to the present invention.

[0073] Fig. 11 is a perspective view showing a modified example of the optical module of the eye disease treatment system illustrated in Fig. 10.

[0074] Fig. 12 is an exploded perspective view of the eye disease treatment system of Fig. 11.

[0075] Fig. 13 is a plan view showing the LED module of the eye disease treatment system of Fig. 11.

[0076] Fig. 14 is a cross-sectional view of the eye disease treatment system of Fig. 11.

[0077] Fig. 16 is a photograph showing a simply constructed test device for verifying the light irradiation effect of the eye care device according to the present invention.

[0078] Figure 17 is a graph showing the test process in time series using the test device illustrated in Figure 16.

[0079] Figure 18 is a photograph showing human corneal epithelial cells for safety evaluation of light irradiation by the test device illustrated in Figure 16.

[0080] Figure 19 is a graph showing changes in the survival rate and proliferation of human corneal epithelial cells according to the light irradiation time by the test device illustrated in Figure 16.

[0081] Figure 20 is a graph showing the amount of tears measured by multi-wavelength LED irradiation in a dry eye animal model.

[0082] Figure 21 is a photograph and graph showing the results of evaluating corneal surface irregularity by multi-wavelength LED irradiation in a dry eye animal model.

[0083] Figure 22 is a photograph and graph showing the results of evaluating the detached corneal surface density and area by multi-wavelength LED irradiation in a dry eye animal model.

[0084] Figure 23 is a photograph and graph showing the results of corneal thickness evaluation using multi-wavelength LED irradiation in a dry eye animal model.

[0085] Figure 24 is a photograph and graph showing the results of analysis of IL-1β expression by multi-wavelength LED irradiation in a dry eye animal model.

[0086] Figure 25 is a photograph and graph showing the results of an analysis of IL-6 expression by multi-wavelength LED irradiation in a dry eye animal model.

[0087] Figure 26 is a photograph and graph showing the results of analysis of TNFα expression by multi-wavelength LED irradiation in a dry eye animal model.

[0088] Figure 27 is a photograph and graph showing changes in the survival rate of retinal pigment epithelial cells according to the multi-wavelength LED irradiation time.

[0089] Figure 28 is a photograph and graph showing changes in the proliferation of retinal pigment epithelial cells according to the multi-wavelength LED irradiation time.

[0090] Figure 29 is a photograph and graph showing the establishment of dry AMD animal model conditions over time after odium iodine treatment.

[0091] Figure 30 is a photograph and graph showing a comparison of ONL thickness in the retina after macular degeneration animal model and multi-wavelength LED treatment.

[0092] Figure 31 is a photograph and graph showing the results of a TUNEL assay in an animal model of macular degeneration after multi-wavelength LED treatment.

[0093] Figure 32 is a photograph and graph showing the results of PKCα-positive cells in the retina after macular degeneration animal model and multi-wavelength LED treatment.

[0094] Figure 33 is a photograph and graph showing the results of analysis of the fluorescence expression intensity of Rhodopsin and RPE65 in an animal model of macular degeneration and after multi-wavelength LED treatment.

[0095] Figure 34 shows photographs showing A) STZ administration for inducing diabetic retinopathy (macular edema), (B) multi-wavelength LED irradiation, (C) blood sugar measurement results of a normal control group, and (D) blood sugar measurement results of a diabetic retinopathy (macular edema) model.

[0096] Figure 35 is a graph showing the change in body weight of a normal control group and an animal model of diabetic retinopathy (macular edema) after STZ administration.

[0097] Figure 36 is a photograph and graph showing a comparison of ONL thickness in the retina after treatment with multi-wavelength LED in an animal model of diabetic retinopathy (macular edema).

[0098] Hereinafter, a treatment system for treating eye diseases, a method for treating eye diseases, and an optical module used therein according to the present invention will be described with reference to the attached drawings.

[0099] The system for treating eye diseases according to the present invention, as illustrated in FIGS. 1 to 9, includes a main body module (10) that covers the user's eyes so that a light module (100) that generates therapeutic light is installed and the light of the light module (100) is irradiated to the user's eyes; and a wearable part (20) that is coupled to the main body module (10) and extends to the side of the user's head to be worn by the user.

[0100] The above main body module (10) is configured to cover the user's eyes so that the light of the optical module (100) that generates therapeutic light is installed and irradiates light to the user's eyes, and various configurations are possible.

[0101] Here, the light irradiated to the user's eyes may irradiate at least one of the user's cornea and retina.

[0102] Accordingly, it is preferable that the light irradiated to the user's eyes be guided by an optical system so that the light is irradiated to the user's cornea and / or retina.

[0103] At this time, when irradiating the user's eyes for the purpose of care, treatment, or symptom relief of the user's retina, it is desirable that the light irradiation intensity and light irradiation conditions (irradiation time, irradiation pattern, etc.) be performed to a degree that does not cause damage to the user's retina.

[0104] For example, the main body module (10) may include a main body part (12) to which an optical module (100) is coupled and to which a wearable part (20) described later is coupled, and a cover part (11) coupled to the main body part (12) to cover the optical module (100).

[0105] The above main body (12) is configured to be coupled with an optical module (100) and a wearable part (20) described later, and various configurations are possible depending on the coupling structure with the optical module (100) and the nose support structure.

[0106] The above main body (12) has a control unit (not shown) built in to control the optical module (100) and may have a shape that crosses both eyes based on the user's face so that the optical module (100) is coupled to the lower side.

[0107] The above control unit may be configured with one or more circuit boards as a configuration for controlling the optical module (100) inside.

[0108] Meanwhile, the control unit may include a communication module for communication with the outside.

[0109] The above communication module is a module for communicating with the outside world by at least one of wired and wireless methods, and can be configured in various ways depending on the communication method.

[0110] For example, the communication module may include at least one communication module such as Bluetooth, Wi-Fi, or Zigbee.

[0111] Additionally, the communication module may be installed in the main body module (10) or in the wearable part (20).

[0112] Meanwhile, optical modules can be coupled to the lower side on the left and right sides respectively to correspond to one pair of eyes of the user.

[0113] Additionally, a nose pad (13) can be coupled between the pair of optical modules (100).

[0114] The above-mentioned wearing part (20) is configured to be connected to the main body module (10) and extended to the side of the user's head so that it can be worn by the user, and various configurations are possible depending on the wearing structure.

[0115] As an example, the above-mentioned wearing part (20) may be configured as a pair by extending from both ends of the main body module (10) toward the user's ears.

[0116] And the end portion of the above-mentioned wearing part (20) may have a structure similar to glasses so that it can be hung on the user's ear.

[0117] Meanwhile, the above-mentioned wearing part (20) may have various coupling structures, such as being coupled to the main body module (10) in a way that the length from the main body module (10) is variable, or being hinge-rotatably coupled so that it can be folded relative to the main body module (10), taking into account the various factors such as the wearer's head size and the distance to the ears.

[0118] That is, for convenience of storage, etc., the wearing part (20) is hinged at both ends of the main body module (10) by a hinge part (21) so that it can be folded and stored with respect to the main body module (20) when not in use.

[0119] And at least one of the main body module (10) and the wearing part (20) may be provided with a terminal part (14) for connection with an external connection terminal (30).

[0120] The above terminal portion (14) is configured to be installed in at least one of the main body module (10) and the wearing portion (20) for connection with an external connection terminal (30), and various configurations are possible depending on the connection structure with the external connection terminal (30).

[0121] In addition, the above-mentioned wearing part (20) may have a built-in battery (40) for supplying power to the optical module (100) and the control unit, although not shown.

[0122] The above battery (40) is installed in the wearable part (20), as shown in FIG. 2b, thereby enabling an even weight distribution overall.

[0123] That is, the battery (40) may be a rechargeable battery such as a lithium-ion battery and may be installed inside along the length of the wearable part (20).

[0124] Meanwhile, it goes without saying that the battery (40) may be installed in addition to the wearing part (20) or may be installed in the main body module (10) as well as the wearing part (20).

[0125] The above optical module (100) is a configuration that generates therapeutic light, and can have any configuration as long as it can be coupled to the main body module (10).

[0126] For example, the optical module (100) may be configured to include an LED module (110) that irradiates therapeutic light and an optical system (101) that guides light irradiated from the LED module (120).

[0127] Here, the optical module (100) is coupled to the main body module (10) by a coupling means (102).

[0128] The above coupling means (102) is a configuration that couples the optical module (100) to the main body module (10), and various configurations are possible.

[0129] As an example, the coupling means (102) may be configured as a part of a housing (not shown) in which the optical module (100) is installed.

[0130] In addition, the above-mentioned coupling means (102) may be configured as a coupling portion (not shown) to which the optical module (100) is coupled, as a part of the main body module (10), particularly the main body portion (12).

[0131] Meanwhile, since the distance between the user's two eyes may vary from person to person, the optical module (100) needs to be adjusted to the distance between the user's eyes.

[0132] Accordingly, the above-mentioned coupling means (102) can be configured so that the distance formed by a pair of optical modules (100), the so-called interfocal distance (PD), is variable according to the distance between the user's eyes.

[0133] At this time, a display scale (15) indicating a position based on the inter-eye distance (PD) may be displayed on the main body (12) of the main body module (10).

[0134] Additionally, depending on the user's wearing condition, there are cases where the direction, i.e., the axial direction, of the optical module (100) facing the eye needs to be aligned with the eye.

[0135] Accordingly, the above-mentioned coupling means can be configured so that the axial direction of the optical module (100) can be changed while it is worn on the user's head.

[0136] The axially variable structure is a structure capable of rotation about one or more axes, and may be a universal joint structure or a structure capable of rotation about at least one axis among the X-axis, Y-axis, and Z-axis.

[0137] The above LED module (110) is a configuration that irradiates therapeutic light and can have various configurations.

[0138] As an example, the LED module (110) may include an LED substrate (112) on which one or more LED elements (111) are installed.

[0139] The above LED element (111) is a configuration that generates therapeutic light, and the wavelength can be selected according to the optical characteristics of K-light.

[0140] In particular, in order to maximize the care (treatment) effect, light irradiation of multiple wavelengths is desirable, and it is preferable that the LED element (111) is composed of multiple elements.

[0141] For example, the LED element (111) may include at least one of a first LED element that irradiates light in a blue wavelength range; a second LED element that irradiates light in a green wavelength range; a third LED element that irradiates light in a red wavelength range; a fourth LED element that irradiates light in an ultraviolet wavelength range; and a fifth LED element that irradiates light in an infrared wavelength range.

[0142] The above first LED element is an LED element that irradiates light in the blue wavelength range, and an LED element that irradiates light of an appropriate wavelength can be selected depending on the level and content of care for the body part being irradiated.

[0143] For example, the first LED element may be an LED element that irradiates light with a wavelength of 435 to 485 nm.

[0144] The above second LED element may be an LED element that irradiates light in the green wavelength range.

[0145] For example, the second LED element may be an LED element that irradiates light with a wavelength of 500 to 600 nm, preferably 500 to 590 nm, and more preferably 500 to 560 nm.

[0146] Meanwhile, the second LED element may be an LED element that emits light with a wavelength of 590±10 nm, taking into account commercially available LED elements.

[0147] The third LED element may be an LED element that emits light in the red wavelength range.

[0148] For example, the third LED element may be an LED element that irradiates light with a wavelength of 610 to 760 nm, particularly 680±10 nm.

[0149] The fourth LED element may be an LED element that irradiates light in the ultraviolet wavelength range.

[0150] The above fourth LED element can be an LED element that irradiates light of wavelengths of UVA (320-400 nm), UVB (290-320 nm), and UVC (200-0 nm).

[0151] Meanwhile, the fourth LED element may be used for disinfection of items carried when used for purposes other than treatment, such as care purposes.

[0152] The fifth LED element above is an LED element that irradiates light in the infrared wavelength range, and an LED element that irradiates light of an appropriate wavelength can be selected depending on the level and content of care for the body part being irradiated.

[0153] The fifth LED element may be an LED element that irradiates light with a wavelength of 750 nm to 25,000 nm. Here, the infrared rays may be classified into near infrared rays (750 nm to 1,500 nm), mid infrared rays (1,500 nm to 3,000 nm), and far infrared rays (3,000 nm to 25,000 nm) depending on the wavelength range.

[0154] Meanwhile, the first to fifth LED elements as described above may be used only as LED elements of one type that irradiate a single light, or at least two types of LED elements among the first to fifth LED elements may be used in combination.

[0155] For example, the LED module (100) can be configured by a combination of a first LED element, a second LED element, and a third LED element.

[0156] As another example, the LED module (100) may be configured by a combination of a first LED element, a second LED element, and a third LED element.

[0157] In addition, the LED module (100) is composed of only two or more wavelengths of light within the same wavelength series, for example, a fifth LED element, and LED elements that irradiate infrared light of 780±10 nm and LED elements that irradiate infrared light of 830±10 nm can be used.

[0158] That is, the optical combination module for the eye disease treatment system according to the present invention can be composed of two or more types of LED elements with different wavelengths, depending on the intended use and purpose.

[0159] Meanwhile, as a specific example of the combination of the LED elements (111), it may be composed of a combination of a first LED element having a wavelength of 590±10 nm, a second LED element having a wavelength of 680±10 nm, a third LED element having a wavelength of 780±10 nm, and a fourth LED element having a wavelength of 830±10 nm.

[0160] In summary, therapeutic light for treating eye diseases can be a combination of light of multiple wavelengths.

[0161] For example, the treatment light may include at least one of a first irradiation light having a blue wavelength; a second irradiation light having a green wavelength; a third irradiation light having a red wavelength; a fourth irradiation light having an ultraviolet wavelength; and a fifth irradiation light having an infrared wavelength.

[0162] As another example, the above treatment light may be composed of a combination of a first light having a wavelength of 590±10 nm, a second light having a wavelength of 680±10 nm, a third light having a wavelength of 780±10 nm, and a fourth light having a wavelength of 830±10 nm.

[0163] Meanwhile, if the energy of the light irradiated to the user's eyes is excessive, the retinal cells may be damaged.

[0164] Accordingly, it is desirable that the total amount of therapeutic light energy irradiated to the user's eyes per hour be less than a preset value.

[0165] Accordingly, in order to reduce power consumption for phototherapy and to eliminate optical interference when combining therapeutic lights, it is preferable that when at least one of the therapeutic lights, i.e., the irradiation lights, is irradiated, the remaining irradiation lights are in an off state.

[0166] As shown in Fig. 15b, it is more preferable that when one of the plurality of light sources is irradiated, the remaining light sources are in an off state.

[0167] Specifically, after the first investigation light (wavelength λ1) is irradiated in a preset first cycle, the second investigation light (wavelength λ2) can be sequentially irradiated in a second cycle, the third investigation light (wavelength λ3) in a third cycle, and the fourth investigation light (wavelength λ4) in a fourth cycle.

[0168] Here, the order and period of the wavelengths (λ1, λ2, λ3, λ4) of the investigation light can be set in various ways.

[0169] Additionally, the power value of the light source can also be set in various ways.

[0170] Meanwhile, it is preferable that the plurality of light sources are irradiated as pulsed light with on / off control.

[0171] When irradiating therapeutic light to the user's eyes in the above pattern, light irradiation can be performed in an optimal state by minimizing power consumption and eliminating interference due to overlapping of irradiation light.

[0172] Meanwhile, in the treatment light irradiation described above, the type of irradiation light (based on wavelength), the number of irradiation lights, and the power value of each irradiation light (in mW, etc.) can be set in various ways.

[0173] If the type of irradiation light (based on wavelength), the number of irradiation lights, and the power value of each irradiation light (in mW, etc.) can be set in various ways, the optimized light irradiation effect can be provided for each user or type of eye disease.

[0174] Meanwhile, as an integrated configuration, the optical module (100) according to the first embodiment may include, as illustrated in FIGS. 6 to 8, an LED module (100) including an LED substrate (112) having one or more LED elements (111) installed thereon; a light tube (120) to which the LED module (100) is coupled at one end; one or more lenses (141) installed in the light tube (120) and emitting light generated by the LED elements (111); a diffusion member (142) coupled to the light tube (120) to diffuse the light; and a fixing member (130) coupled to the light tube (120) to fix the lens (141) and the diffusion member (142).

[0175] The above-mentioned tube (120) is configured such that the LED module (100) is combined at one end, and various configurations are possible.

[0176] As an example, the above-mentioned tube (120) may have a hollow cylinder structure with both ends open.

[0177] In addition, the inner surface of the above-mentioned light tube (120) can form a reflective surface so that light generated from the LED module (100) is reflected.

[0178] The above lens (141) is installed in the optical tube (120) and is configured to emit light generated by the LED element (111), and may be installed in one or more configurations.

[0179] For example, the lens (141) may be configured as a plano-concave (planar concave) lens as a convex lens.

[0180] At this time, the flat surface of the lens (141) can be installed so as to face the LED module (100).

[0181] Meanwhile, the above-mentioned tube (120) can have various structures depending on the joint structure with the lens (141) and the diffusion member (142), and as shown in FIG. 7b, it can be composed of a large-diameter portion (121) having an inner diameter corresponding to the outer peripheral surface of the edge of the lens (141), and a small-diameter portion (122) extending from the large-diameter portion (121) and having an inner diameter smaller than that of the large-diameter portion (121).

[0182] At this time, the boundary portion of the large diameter portion (121) and the small diameter portion (122) may be installed to form a step and support the outer surface of the lens (131).

[0183] The above diffusion member (142) is configured to diffuse light by being coupled to the other end of the light tube (120), and various configurations are possible.

[0184] Specifically, the diffusion member (142) may cause fatigue to the user's eyes due to the strong intensity of light generated from the LED element (111). To prevent this, various diffusion members may be used depending on the type of diffusion as a diffusion member that diffuses the light.

[0185] Meanwhile, one or more auxiliary cylinders (142a, 142b) may be installed inside the above-mentioned tube (120) to install the diffusion member (142).

[0186] And, the above-mentioned tube (120) may have a sealing member (142c) such as an O-ring installed to seal the surface where it is combined with the LED substrate (112).

[0187] The above fixed joint (130) is configured to be connected to the other end of the tube (120) to fix the diffusion member (142), and various configurations are possible.

[0188] For example, the fixed joint (130) may include a female screw portion that is screw-connected to a male screw portion formed on the outer surface of the barrel (120), as shown in FIG. 7b, and a rim portion (131) on the inner side that brings the diffusion member (142) into close contact with the end of the barrel (120).

[0189] Meanwhile, the optical system (101) can be configured in various ways depending on the direction of irradiation of the therapeutic light, etc.

[0190] For example, an optical module (100) according to the present invention, as illustrated in FIGS. 10 to 14, includes: a light tube (120) having a hollow cylindrical structure; an LED module (110) including an LED substrate (112) coupled to one end of the light tube (120) and having a through-hole (113) corresponding to the hollow portion of the light tube (120) formed therein and having a plurality of LED elements (111) installed along a circumferential direction; a reflective member (151) coupled to one end of the light tube (120) and reflecting light generated from the plurality of LED elements (111) toward the hollow portion of the light tube (120); a spherical lens (152) installed in the light tube (120) and converging light reflected by the reflective member (151); It may include a guide lens (153) that guides light passing through the above-mentioned spherical lens (152) into a preset area.

[0191] The above-mentioned tube (120) has a hollow cylinder structure and can be configured in various ways.

[0192] For example, the above-described tube (120) may include a large-diameter portion (124) having an inner diameter corresponding to the outer diameter of the guide lens (153) described later, and a small-diameter portion (125) having an inner diameter corresponding to the outer diameter of the spherical lens (152).

[0193] The above-mentioned large diameter portion (124) is a portion having an inner diameter corresponding to the outer diameter of the guide lens (153) described later, and may have an inner diameter corresponding to the outer diameter of the guide lens (153) so that the guide lens (153) can be installed precisely.

[0194] Meanwhile, the large diameter portion (124) may be formed with a step portion (124a) that prevents axial movement of the guide lens (153) to prevent axial movement.

[0195] By forming the step portion (124a) above, the barrel (120) can have a medium-diameter portion (126) formed between the large-diameter portion (124) and the small-diameter portion (125).

[0196] The above-mentioned small diameter portion (125) is a portion having an inner diameter corresponding to the outer diameter of the spherical lens (152), and may have an inner diameter corresponding to the outer circumferential surface of the spherical lens (152) so that the spherical lens (152) can be precisely installed.

[0197] At this time, the small diameter portion (125) may be formed with a catch (125a) to prevent axial movement of the spherical lens (152).

[0198] And, in the above small diameter portion (125), a pressing member (141) that presses the spherical lens (152) in the axial direction can be installed on the opposite side where the catch (125a) is formed.

[0199] The above-mentioned pressurizing member (140) is configured to pressurize the spherical lens (152) in the axial direction at the opposite side where the catch (125a) is formed by being installed in the small diameter portion (125), and an opening is formed in the central portion to allow light to propagate.

[0200] Meanwhile, the pressurizing member (140) can be pressed toward the spherical lens (152) by the LED substrate (112) when the LED module (110) is directly or indirectly connected to the barrel (120).

[0201] At this time, it is preferable that the pressurizing member (140) has a material capable of elastic deformation, such as synthetic resin or rubber, to ensure close contact with the spherical lens (152).

[0202] The above LED module (110) is configured to be connected to one end of the tube (120), has a through-hole (113) corresponding to the hollow of the tube (120), and includes an LED substrate (112) on which a plurality of LED elements (111) are installed along the circumferential direction, and various configurations are possible.

[0203] The above LED element (111) is identical or similar to the LED element (111) described above, so a detailed description is omitted.

[0204] The above LED substrate (112) is connected to one end of the tube (120), and a through hole (113) corresponding to the hollow portion of the tube (120) is formed, and a plurality of LED elements (111) are installed along the circumferential direction.

[0205] The above-mentioned through hole (113) is formed to a sufficient size so that light reflected by the reflective member (151) described later in the LED substrate (112) can pass through.

[0206] Meanwhile, the LED elements (111) installed on the LED substrate (112) are installed to irradiate light in the opposite direction to the light tube (120).

[0207] The above reflective member (151) is configured to be coupled to one end of the tube (120) and reflect light generated from the plurality of LED elements (111) toward the hollow portion of the tube (120), and various configurations are possible.

[0208] For example, the reflective member (151) may have an inner surface formed with a preset curvature so as to guide light to the user's eyes, as shown in FIGS. 10 and 12.

[0209] In addition, the reflective member (151) may be combined with a protective member (152) to prevent external impact, damage, etc., either integrally or as a separate member.

[0210] The above protective member (152) is a component provided to prevent the reflective member (151) from external impact, damage, etc., and can be configured in various ways, such as being formed integrally with the reflective member (151) or being combined separately.

[0211] Meanwhile, the reflective member (151) and the protective member (152) can be combined with the LED module (110) to the light tube (120) in various structures as one reflective module (150).

[0212] The above reflective module (150) is a module composed of the reflective member (151) and the protective member (152) for combination with the joining member (140) and the LED module (110) described later, and various configurations are possible.

[0213] For example, the reflective module (150) may include an auxiliary cylinder (154) that couples the LED substrate (112) to the coupling member (140) when the reflective member (151) and the protective member (152) are coupled to the coupling member (140) by a screw or the like.

[0214] The above auxiliary cylinder (154) is configured to couple the LED substrate (112) to the coupling member (140) when the reflective member (151) and the protective member (152) are coupled to the coupling member (140) by a screw or the like, and various configurations are possible.

[0215] For example, the auxiliary cylinder (154) may have an inner diameter corresponding to the outer diameter of the reflective member (151) so that the reflective member (151) can be inserted, and a step (154a) corresponding to the thickness of the LED substrate (112) may be formed so that the LED substrate (112) can be coupled to the coupling member (140).

[0216] In addition, the auxiliary cylinder (154) may be formed with a cut-out (154a) that exposes the terminal portion (112a) to the outside so that the terminal portion (112a) for control and power supply of the LED substrate (112) can be connected to the outside.

[0217] Meanwhile, the reflective module (150) and the LED module (110) can be combined with a coupling member (140) for coupling with the optical tube (120).

[0218] The above-mentioned connecting member (140) is configured to be connected to the optical tube (120) in a state in which the reflective module (150) and the LED module (110) are connected, and various configurations are possible depending on the connecting structure with the optical tube (120).

[0219] For example, the above-mentioned joining member (140) may include a joining cylinder (142) into which the outer surface of the barrel (120) is inserted, and a joining flange (143) extending radially from the joining cylinder (142) to which the reflective module (150) and the LED module (110) are joined.

[0220] The above spherical lens (152) is installed in the optical tube (120) and is configured to converge light reflected by the reflective member (151), and various configurations are possible.

[0221] The above guide lens (153) is configured to guide light passing through the spherical lens (152) into a preset area, and various configurations are possible.

[0222] Meanwhile, the optical module (100) having the above configuration can be configured as an optical module of the eye disease treatment system illustrated in FIGS. 1 to 9, and at this time, a coupling part (190) for coupling with the main body module (10) can be coupled for installation into the main body module (10).

[0223] The above-mentioned connecting portion (190) is configured for connection with the main body module (10), and can have various configurations.

[0224] For example, the above-mentioned coupling part (190) may include a coupling cylinder (191) into which the barrel (120), particularly the coupling cylinder (142), is inserted and coupled, and a coupling protrusion (192) that protrudes radially from the outer surface of the coupling cylinder (191) and is coupled with the main body module (10).

[0225] And the above-mentioned coupling cylinder (191) can be coupled with the above-mentioned barrel (120), especially the above-mentioned coupling cylinder (142), by various structures.

[0226] Meanwhile, when the system for treating eye diseases according to the present invention has a structure similar to glasses as illustrated in FIGS. 1 to 14, it is necessary to confirm whether light is stably irradiated to the user's eyes when worn.

[0227] Accordingly, the main body module (10) may additionally be equipped with a camera unit (300) to check whether light is stably irradiated to the user's eyes.

[0228] The above camera unit (300) is configured to acquire an image of the user's eye and track whether the light irradiated by the optical module (100) described above is stably irradiated to the user's eye, and may include an image pickup device (not shown) and an optical system that forms an image including the user's eye with the image pickup device.

[0229] In particular, when the system for treating eye diseases according to the present invention has a structure similar to glasses as illustrated in FIGS. 1 to 14, the camera unit (300) is installed between a pair of optical modules (100) and configured to enable wide-angle photography such as a fish-eye lens, thereby obtaining images of a pair of eyes of the user.

[0230] Meanwhile, considering that the system for treating eye diseases according to the present invention is worn in close contact with the user's face and thus may not have sufficient lighting conditions for acquiring images of the eyes, the camera unit (300) may include a camera that recognizes at least one of infrared rays and visible light.

[0231] In particular, it is preferable that the camera be a camera that can shoot in the infrared range as well as in the visible light range.

[0232] Meanwhile, in order to implement the above function, the camera unit (300) may include, as shown in FIGS. 2A to 2E, an imaging unit (310) that acquires images of a pair of eyes of a user; an optical system (320) that induces light so that the imaging unit (310) can acquire images of a pair of eyes while the main body module (10) is worn by the user; and an image processing unit that processes the images acquired by the imaging unit (310).

[0233] The above-mentioned imaging unit (310) is configured to acquire images for one pair of eyes of the user, and may be configured as an imaging module equipped with a CCD image sensor, a CMOS image sensor, etc.

[0234] The above optical system (320) is configured to induce light so that the scratch portion (310) can obtain images of one pair of eyes while the main body module (10) is worn by the user, and needs to be maintained at a preset distance from the user's forehead so that one camera can capture both pairs of eyes.

[0235] Accordingly, the optical system (320) is preferably positioned between the user's eyebrows based on the state in which the main body module (10) is worn by the user, and is preferably positioned 15 mm to 40 mm from the user's retina (approximately indicated as L in FIG. 2b).

[0236] For reference, considering that the distance between the objective lens of the optical module (100) and the cornea is preferably 1.5 cm to 2.0 cm, and particularly 1.7 cm, it is preferable that the distance between the objective lens of the optical system (320) and the cornea be set to be greater than the distance between the objective lens of the optical module (100) and the cornea.

[0237] For example, the distance between the objective lens of the optical system (320) and the cornea can be set to be 5 mm to 15 mm greater than the distance between the objective lens of the optical module (100) and the cornea.

[0238] And, it is preferable that the optical system (320) has an angle of view of 120° or more based on the image formed on the imaging unit (310).

[0239] Meanwhile, the optical system (320) and the imaging unit (310) can be coupled to each other by a fixing member (340), as shown in FIGS. 2c to 2e.

[0240] The above-mentioned fixed member (340) is configured to be coupled to the camera housing (390) so as to pressurize the rear surface of the imaging unit (310) toward the optical system (320), and various configurations are possible.

[0241] The image processing unit is a configuration that processes the image acquired by the imaging unit (310), and can have various configurations depending on the processing level of the image captured by the imaging unit (310).

[0242] As an example, the image processing unit may be configured to simply process image data such as raw data files and compressed files in jp format so that the image data can be transmitted to a separate control unit.

[0243] As another example, the image processing unit may include an image processing chip (331) for fast image processing and analysis.

[0244] The above image processing chip (331) may be any chip capable of processing an image acquired by the imaging unit (310) and analyzing the processed image.

[0245] And the image processing chip (331) can be mounted on the PCB portion (330), and the PCB portion (330) can be installed by being fixed to the back surface of the fixing member (340) described above.

[0246] And the PCB section (330) can be connected to the imaging section (310) by a flexible cable (332).

[0247] In addition, the PCB section (330) can be connected to the main PCB by a flexible cable (333) for controlling the image processing chip (331), controlling the imaging section (310), etc.

[0248] In particular, the flexible cable (332) connecting the imaging unit (310) and the PCB unit (330) is connected in a U-shape around the fixing member (240), thereby minimizing the space in which the imaging unit (310) and the PCB unit (330) are installed.

[0249] That is, the above-mentioned imaging unit (310) and the PCB unit (330) are fixed to the front and back surfaces, respectively, with the fixing member (340) interposed therebetween, thereby minimizing the installation space.

[0250] Meanwhile, the image processing unit, particularly the image processing chip (331), as illustrated in FIG. 15A, may be configured to perform eye treatment monitoring, including an eye object search step for searching for an eye object corresponding to an eye in a primary image acquired by the imaging unit (310); an eye object extraction step for extracting the eye object searched in the eye object search step; and a normal judgment step for analyzing the eye object extracted in the eye object extraction step to determine whether light irradiation is performed normally.

[0251] The above eye object search step is a step of searching for an eye object corresponding to an eye in the primary image acquired by the imaging unit (310), and can be performed by various methods.

[0252] Here, the primary image is the image itself acquired by the imaging unit (310), and as described above, can be image data such as a raw data file or a compressed file in jp format.

[0253] The above eye object is an area corresponding to the user's eye in the primary image to determine whether light irradiation is performed normally, and the search for the eye object can be performed using various image processing methods.

[0254] In particular, the above eye object search step can be performed by an artificial intelligence program learned through various eye image data captured in advance and an actual shooting process.

[0255] Here, the above eye object search step, and further, eye treatment monitoring, can be performed at 30 frames (approximately 2 seconds) considering the processing speed.

[0256] The above eye object extraction step is a step of extracting the eye object searched in the eye object search step in order to perform the normal judgment step described later, and can be performed using the so-called image cropping method.

[0257] The above normal judgment step is a step of analyzing the eye object extracted in the eye object extraction step to determine whether light irradiation is performed normally, and can be performed by various methods.

[0258] In particular, the above normal judgment step can be performed by an artificial intelligence program learned through various types of eye image data that have been previously captured and an actual shooting process.

[0259] As training data, images of various eye movements can be trained to distinguish between states suitable for phototherapy and states not suitable for phototherapy, such as eye opening, eye closing, and abnormal eye movements.

[0260] As an example of the above normal judgment step, if the eye closure continues for a preset period of time based on the extracted eye object, it may be judged as incurable and phototherapy may be stopped or terminated.

[0261] In addition, as an example of the above normal judgment step, if the eye closure continues for a preset period of time based on the extracted eye object, it is determined that treatment / care cannot proceed, and light therapy is stopped, and a stimulus such as sound or vibration is applied to the user to attempt to change to a state where light therapy / light care is possible.

[0262] If the user is judged to be in an open state by re-performing the eye object search step or normal judgment step after being stimulated, light therapy / light care can be performed again.

[0263] In relation to the artificial intelligence program, at least one of the eye object search step, the eye object extraction step, and the normal judgment step can be performed by the artificial intelligence program.

[0264] In particular, at least one of the above eye object search step and the above normal judgment step can be performed by an artificial intelligence program.

[0265] By obtaining an image of the user's eyes by the camera unit (300) through the above configuration, it is possible to check the light irradiation status when the light is irradiated by the pair of optical modules (100), and thus control of the light irradiation can be performed more effectively.

[0266] Meanwhile, the eye object search step, the eye object extraction step, and the normal judgment step, as described above, may be performed as an app on a smart device such as a smart phone, smart pad, or dedicated device connected via wireless communication such as Bluetooth instead of being performed in the image processing unit installed in the main body (12).

[0267] To this end, the smart device may be installed with an app for wireless control of the eye disease treatment system according to the present invention, reception of eye images, etc. from the eye disease treatment system, etc.

[0268] Meanwhile, in performing the above normal judgment step, the image of the extracted eye object includes a reflection image of the therapeutic light formed on the retina, and by comparing the positions of the pupil and the reflection image of the therapeutic light within the eye object, it is possible to confirm whether the therapeutic light is normally irradiated to the user's eye.

[0269] If the positions of the pupil and the reflected image of the treatment light within the eye object are misaligned as a result of comparison, the error can be calculated and an instruction can be given to correct the horizontal position of the user's eye.

[0270] The above horizontal position can be defined as the position of the optical module (100) in the direction of approaching and moving away from the nose with the nose as the center while the user wears it on the face.

[0271] Meanwhile, as a result of conducting animal tests using an eye disease treatment system having the above configuration, it was confirmed that it has a treatment and alleviation effect on eye diseases such as dry eye, macular degeneration, and macular edema.

[0272] That is, the system for treating eye diseases according to the present invention can be used as an eye disease treatment device for treating eye diseases such as dry eye, macular degeneration, and macular edema.

[0273] - Test Example 1 (Dry Eye Test)

[0274] A. Test conditions

[0275] 1) Test cells

[0276] In vitro test cell: HCE-T cell (Human corneal epithelial cell line)

[0277] 2) Media and reagents

[0278] a) Cell culture

[0279] DMEM, FBS10%, 1% Antibiotics, Trypsin

[0280] b) Analytical reagent

[0281] - MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)

[0282] - DMSO

[0283] 3) In vivo test animals:

[0284] a) Test animal strain: C57BL / 6

[0285] b) Test animal sex / quantity: female / 15 animals

[0286] D) Test animal weight / age: 18~20 g / 7 weeks old

[0287] a) Inducing dry eye

[0288] - Subcutaneous injection of saline solution containing scopolamine hydromide 0.5 mg / 0.2 ml, 4 times daily for 17 days

[0289] 4) Test staining reagent

[0290] a) H&E stain reagent

[0291] - Hematoxylin, Eosin

[0292] - EtoH, Xylene

[0293] b) Immunohistochemistry (IHC) reagents

[0294] - Primary antibody

[0295] : IL-6 (abcam)

[0296] : IL-1 (abcam)

[0297] : TNF-α (abcam)

[0298] - Secondary antibody

[0299] : Horse anti-mouse IgG ab (Vector)

[0300] : Goat anti-Rabbit IgG ab (Verctor)

[0301] - ABC kit (Vector)

[0302] - DAB stain (Vector)

[0303] 5) Test equipment

[0304] Considering that this is a test to verify the effectiveness of the eye disease treatment system according to the present invention, the test equipment was configured as shown in Fig. 16.

[0305] a) Wavelength conditions

[0306] LEDs of 680 nm, 780 nm, and 830 nm, where each wavelength can be varied by ±10 nm.

[0307] b) Light intensity (irradiation energy is the average light output of each LED)

[0308] 12.3 mW (680 nm) + 14.9 mW (780 nm) + 10.6 mW (830 nm) = 37.8 mW / cm 2 , 2 minute survey

[0309] About 4.5 J / cm 2

[0310] B. Test method

[0311] 1) In vitro safety evaluation of multi-wavelength LEDs (test equipment shown in Figure 16) targeting human corneal epithelial cells

[0312] - Culturing HCE-T cells in medium

[0313] - Dispense into 12-well plates (multipurpose home plates) when 80% cultured

[0314] - Irradiate the plate containing HCE-T cells using a multi-wavelength (680nm±10nm, 780nm±10nm, 830nm±10nm) LED light source module.

[0315] a) Investigate light according to time and check cell viability through cell growth after 24 hours (0, 0.5, 1, 2, 4, 8 minutes) (MTT assay)

[0316] b) 37.8 mW / cm 2 , 2 minutes (4.5 J / cm 2 ) after fixation with light irradiation for 0, 24, 48, and 72 hours, cell proliferation rate was confirmed through proliferation assay (MTT assay)

[0317] ⓛ MTT assay

[0318] - Corneal epithelial cells (HCE-T) were cultured in an incubator at 5% CO2 and 37℃ using DMEM (Dulbecco's Modified Eagle Medium) medium.

[0319] - Corneal epithelial cells were seeded in a 12-well plate and irradiated with a multi-wavelength LED light source after 24 hours.

[0320] - The light source is irradiated by aligning the cylindrical end of the LED with one well of a 12-well plate containing cells. (Distance from the cylinder to the cells: 17 mm)

[0321] - After culturing for 0, 24, 48, and 72 hours, remove the medium, add 50 μL of MTT solution and 100 μL of medium, and incubate for 4 hours in an incubator with light blocked.

[0322] - After 4 hours, remove the reactant, add 100 μL of DMSO, and measure the absorbance at 595 nm using a spectrophotometer.

[0323] 2) In vivo efficacy evaluation of multi-wavelength LED in dry eye animal models

[0324] ⓛ Inducing dry eyes

[0325] - To induce a dry eye animal model, scopolamine hydrobromide was administered subcutaneously or intraperitoneally four times a day for 17 days at a concentration of 2.5 mg / mL.

[0326] - One week after inducing dry eye, light was applied 5 times to the entire eye area using a multi-wavelength LED light source module (wavelengths are 680 nm ± 10 nm, 780 nm ± 10 nm, and 830 nm ± 10 nm).

[0327] - After producing 30 models, 5 models were randomly selected from each test group to conduct the test.

[0328] - After 17 days, the amount of tears and corneal surface irregularity were visually assessed and the tissue was removed.

[0329] - The test group was divided into three groups as shown in Table 1 and conducted according to the schedule in Figure 17.

[0330] Control (n=5) Normal control group (saline solution) Dry eye (n=5) Group induced dry eye with scopolamine hydrobromide Dry eye + Tx (n=5) Group irradiated with LED after inducing dry eye

[0331] ② Visual observation

[0332] - On the 17th day of inducing dry eye, tear volume was measured for 1 minute using Absorbent Paper Point size 30.

[0333] - After fixing the mouse, analyze the extent to which tears are absorbed between the eyelid and the eye.

[0334] - To evaluate corneal irregularity, intracorneal ring segments were imaged using a dissecting microscope, and then divided into four stages to evaluate corneal surface irregularity observed in the control group that did nothing. Irregularity was set to 0 points (no damage) and the evaluation was conducted as shown in Table 2.

[0335] Grade: Corneal surface irregularity score 0 No damage score 1 Slightly irregular score 2 Irregular less than 50% circle Irregularity less than 50% score 3 Irregular greater than 50% circle Irregularity greater than 50%

[0336] ③ Histological observation

[0337] - To ensure objectivity, the right eyes of all animals were removed en bloc after the test was completed for each group. After fixation in 10% formalin solution, the tissues were infiltrated with 15% and 30% sucrose. They were solidified using OCT and frozen into 10 μm sections.

[0338] - Corneal detachment density and area were measured and analyzed by performing H&E staining, and thickness was measured and then analyzed.

[0339] To assess the degree of corneal inflammation, we stained the proinflammatory markers IL-6, IL-1β, and TNFα. The expression level was confirmed using DAB and analyzed using a tissue microscope.

[0340] D. Tests and Results

[0341] 1) In vitro safety evaluation of multi-wavelength LED targeting human corneal epithelial cells (see Figure 18)

[0342] - Measurement of cell survival rate through cell viability 24 hours after light exposure

[0343] - Multi-wavelength LED irradiation at each time point of 0, 0.5, 1, 2, 4, and 8 minutes did not reduce the cell viability of human corneal epithelial cells. In other words, it was determined that there was no cytotoxicity, and multi-wavelength LED showed a tendency to increase cell proliferation, as shown in Figure 19.

[0344] 2) In vivo efficacy evaluation of multi-wavelength LED in dry eye animal models (Table 3)

[0345] - After inducing dry eye, tear volume was measured using absorbent paper point size 30 on the 17th day. The normal control group measured an average of 9.2 ± 1.4 mm, while the dry eye animal model showed a significant 73.8% decrease with an average of 2.4 ± 0.1 mm.

[0346] - On the other hand, the tear volume of the multi-wavelength LED treatment group was measured at 6.7 ± 0.7 mm, a significant increase of 175.5% compared to the tear volume of the dry eye animal model. There was no significant difference between the control group and the LED treatment group.

[0347] - Therefore, as shown in Table 3 and Figure 20, the dry eye animal model used in this test showed a significant decrease in tear amount compared to the normal control group, and it was determined that the multi-wavelength LED significantly increased the tear amount reduced by dry eye.

[0348] - Table 3 shows changes in tear volume due to dry eye and multi-wavelength LED treatment.

[0349] Tear measurement (mm)Control (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average9.252.426.67SEM1.440.110.65

[0350] - When dry eye occurs, corneal protection by tears does not occur, resulting in a phenomenon in which the corneal surface becomes uneven. Therefore, in this test, the irregularity of the corneal surface was observed under a dissecting microscope 17 days after inducing dry eye, and three evaluators evaluated each in a blind manner.

[0351] - As a result of analyzing the average irregularity evaluation scores of three evaluators, the normal control group was measured to have an average of 0.6 ± 0.2, as shown in Table 4 and Figure 21, while the dry eye animal model had an average of 2.4 ± 0.3, showing a significant increase of 295.8% in the corneal surface irregularity score.

[0352] In contrast, the corneal surface irregularity score of the multi-wavelength LED treatment group was measured at 1.4 ± 0.2, a significant 41.1% decrease compared to the irregularity score of the dry eye animal model. This figure is similar to that of the normal control group. There was no significant difference between the control group and the LED treatment group.

[0353] - Table 4 shows the evaluation of corneal surface irregularity by dry eye and multi-wavelength LED treatment.

[0354] Corneal irregularity scoreControl (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average0.602.381.40SEM0.220.250.22

[0355] - On the 17th day of inducing dry eye, all animals were sacrificed, the eyes were removed, and H&E staining of the cornea was performed.

[0356] - Corneal H&E stained images were analyzed using ImageJ software (NIH), counting the areas where the corneal surface had detached, dividing the number by the uniform area to measure the detached corneal surface density, and then analyzed. The area of ​​the detached cornea was measured using ImageJ and analyzed.

[0357] - As shown in Figure 22, the density analysis results showed that the normal control group had an average density of 1.1 ± 0.2, while the dry eye animal model had a significantly increased corneal surface density of 156.3%, with an average density of 2.7 ± 0.3.

[0358] - On the other hand, the detached corneal surface density of the multi-wavelength LED treatment group was measured at an average of 0.9 ± 0.3, which was significantly reduced by 66.1% compared to the detached corneal surface density of the dry eye animal model.

[0359] - Analysis of the area of ​​detached cornea showed that the normal control group had an average of 0.4 ± 0.1 μm 2 , whereas the dry eye animal model had an average of 1.0 ± 0.2 μm 2 The corneal area that fell to the area of ​​the lesion significantly increased by 174%.

[0360] - On the other hand, the average detached corneal surface area in the multi-wavelength LED treatment group was 0.2 ± 0.1 μm 2 The area of ​​detached corneal surface was significantly reduced by 81.4% compared to the area of ​​detached corneal surface in the dry eye animal model. There was no significant difference between the control group and the LED treatment group.

[0361] - Tables 5 and 6 show the evaluation of corneal surface density and area detached by dry eye and multi-wavelength LED treatment, respectively.

[0362] Corneal detach densityControl (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average1.062.720.92SEM0.220.330.31

[0363] Corneal detachment area (μm 2 )Control (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average0.371.020.19SEM0.080.190.07

[0364] - The corneal surface density and area were measured using H&E staining, and then the corneal thickness was measured and analyzed.

[0365] - As shown in Figure 23, the analysis of corneal thickness showed that the normal control group had an average thickness of 26.8 ± 0.4 μm, while the dry eye animal model had an average thickness of 24.2 ± 0.5 μm, a significant decrease of 9.6% in corneal thickness.

[0366] - On the other hand, the corneal thickness of the multi-wavelength LED treatment group was measured at an average of 25.9 ± 0.5 μm, which was a significant increase of 7.1% compared to the corneal thickness of the dry eye animal model.

[0367] - Table 7 shows the results of analysis of changes in corneal thickness due to dry eye and multi-wavelength LED treatment.

[0368] Corneal epidermal thickness (μm)Control (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average26.7724.2025.91SEM0.410.540.45

[0369] - Immunohistochemical staining was performed on sections of the excised eye to measure the expression of inflammatory cytokines.

[0370] - As shown in Figure 24, when stained with IL-1β and the DAB image was analyzed with the image analysis program ImageJ (NIH), the normal control group measured an average intensity of 4.6 ± 1.0, while the dry eye animal model showed an average intensity of 21.1 ± 2.9, indicating a significant increase in IL-1β expression by 359.2%.

[0371] - On the other hand, the IL-1β expression in the multi-wavelength LED treatment group was measured at an average of 8.1 ± 1.2, which was significantly reduced by 61.5% compared to the IL-1β expression level in the dry eye animal model. There was no significant difference between the control group and the LED treatment group.

[0372] - Table 8 shows the results of the analysis of IL-1β expression levels by dry eye and multi-wavelength LED treatment.

[0373] IL-1β DAB intensityControl (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average4.5921.078.11SEM1.002.901.24

[0374] - Next, immunohistochemical staining was performed to measure the expression level of IL-6 as an inflammatory cytokine.

[0375] - As shown in Figure 25, when stained with IL-6 and the DAB image was analyzed with the image analysis program ImageJ (NIH), the normal control group measured an average intensity of 5.4 ± 1.1, while the dry eye animal model showed an average intensity of 18.1 ± 2.1, indicating a significant increase in IL-6 expression by 232.1%.

[0376] - On the other hand, IL-6 expression in the multi-wavelength LED treatment group was measured at an average of 5.1 ± 0.9, which was significantly reduced by 72% compared to the IL-6 expression level in the dry eye animal model. There was no significant difference between the control group and the LED treatment group.

[0377] - Table 9 shows the results of the analysis of IL-6 expression levels by dry eye and multi-wavelength LED treatment.

[0378] IL-6 DAB intensityControl (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average5.4418.075.06SEM1.132.090.92

[0379] - Next, immunohistochemical staining was performed to measure the expression level of TNFα as an inflammatory cytokine.

[0380] - As shown in Figure 26, when staining with TNFα and analyzing the DAB image with the image analysis program ImageJ (NIH), the normal control group measured an average intensity of 0.6 ± 0.2, while the dry eye animal model showed an average intensity of 14.7 ± 2.9, indicating a significant increase in TNFα expression by 2547%.

[0381] - On the other hand, the TNFα expression in the multi-wavelength LED treatment group was measured at an average of 6.7 ± 1.1, which was significantly reduced by 54.6% compared to the TNFα expression level in the dry eye animal model. There was no significant difference between the control group and the LED treatment group.

[0382] - Table 10 shows the results of the analysis of TNFα expression levels by dry eye and multi-wavelength LED treatment.

[0383] TNFα DAB intensityControl (n=5)Dry eye (n=5)Dry eye +Tx (n=5)Average0.5514.676.66SEM0.212.871.06

[0384] A. Test Results Conclusion

[0385] 1) This test used human corneal epithelial cells to evaluate the safety of multi-wavelength LEDs that simultaneously irradiate three wavelengths of 630 nm, 780 nm, and 850 nm. It was confirmed that the treatment of human corneal epithelial cells with multi-wavelength LEDs was not harmful, as it did not reduce cell viability or cell proliferation over time depending on the energy.

[0386] 2) Afterwards, macroscopic and histological observations were performed on mice that were induced to have dry eye for 17 days in a dry environment with scopolamine as an animal model of dry eye, and the Tx group that was irradiated with multi-wavelength LED five times. As a result of measuring the tear amount first, compared to the dry eye animal model, the Tx group significantly increased the tear amount by 175.5% compared to the dry eye animal model expression amount.

[0387] 3) In addition, in the corneal surface irregularity evaluation, three evaluators tested blindly and confirmed that the corneal surface irregularity score significantly increased by 295.8% compared to the control group in the dry eye animal model, and was significantly reduced by 41.1% compared to the expression level in the dry eye animal model in the Tx group.

[0388] 4) Subsequently, in the histological evaluation, it was confirmed that the density of the detached corneal surface increased by 156.3% in the dry eye animal model compared to the control group, whereas it was significantly reduced by 66.1% in the Tx group. In addition, as a result of analyzing the detached corneal surface area, it was confirmed that the detached surface area, which was significantly increased by 174% in the dry eye animal model compared to the control group, was significantly reduced by 81.4% in the Tx group compared to the expression level in the dry eye animal model.

[0389] 5) As a result of measuring corneal thickness, it was confirmed that the Tx group significantly increased the corneal thickness by 7.1% compared to the expression level in the dry eye animal model, which was significantly reduced by 9.6% compared to the normal control group, as in the previous results.

[0390] 6) In addition, DAB images of IL-1β, IL-6, and TNFα were analyzed through immunohistochemical staining to measure the expression level of inflammatory cytokines. First, IL-1β, which was significantly increased by 359.2% in the normal control group compared to the dry eye animal model, was significantly reduced by 61.5% in the Tx group compared to the dry eye animal model expression level.

[0391] 7) As a result of the IL-6 analysis, it was confirmed that the IL-6 expression level in the normal control group significantly increased by 232.1% compared to the dry eye animal model, but was significantly reduced by 72% in the Tx group.

[0392] 8) TNFα results also showed that the TNFα expression level in the normal control group significantly increased by 2547% compared to the dry eye animal model, but in the Tx group, it was significantly reduced by 54.6% compared to the dry eye animal model expression level.

[0393] 9) Based on the results of this test, it was determined that multi-wavelength LEDs have no toxicity to corneal epithelial cells, significantly reduce the level of inflammatory cytokines induced in the cornea due to dry eye in an animal model induced with dry eye, and significantly increase tear volume, thereby recovering corneal damage.

[0394] -Test Example 2 (Macular Degeneration Test)

[0395] A. Test conditions

[0396] 1) Test cells

[0397] In vitro test cell (cell): ARPE-19 cell (Human Rentinal Pigment Epithelial Cell line, ATCC, #CRL-2302)

[0398] 2) Media and reagents

[0399] a) Cell culture

[0400] DMEM, FBS10%, 1% Antibiotics, Trypsin

[0401] b) Analytical reagent

[0402] - MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)

[0403] - DMSO

[0404] 3) In vivo test animals:

[0405] a) Test animal strain: SD rat

[0406] b) Test animal sex / quantity: 22 males

[0407] D) Test animal weight / age: 150~200 g / 6 weeks old

[0408] 4) Induction of macular degeneration

[0409] - NaIO3 Physiological saline solution containing 35 mg / kg

[0410] 4) Test staining reagent

[0411] a) H&E stain reagent

[0412] - Hematoxylin, Eosin

[0413] - EtoH, Xylene

[0414] b) TUNEL stain reagent

[0415] -FITC TUNEL assay kit (BioActs)

[0416] -PI staining (sigma)

[0417] c) Immunohistochemistry (IHC) reagents

[0418] - Primary antibody

[0419] : RPE65 (abcam)

[0420] : Rhodopsin (abcam)

[0421] : PKC-α (Santcruz)

[0422] - Secondary antibody

[0423] : Horse anti-Rabbtit IgG ab, Alexa Fluor TM 555 (ThermoFisher)

[0424] : Goat anti-Mouse IgG ab, Alexa Fluor TM 488 (ThermoFisher)

[0425] - DAPI (4',6-diamidino-2-phenylindole)

[0426] 5) Test equipment

[0427] Considering that this is a test to verify the effectiveness of the eye disease treatment system according to the present invention, the test equipment was configured as shown in Fig. 16.

[0428] a) Wavelength conditions

[0429] LEDs of 680 nm, 780 nm, and 830 nm, where each wavelength can be varied by ±10 nm.

[0430] b) Light intensity (irradiation energy is the average light output of each LED)

[0431] 12.3 mW (680 nm) + 14.9 mW (780 nm) + 10.6 mW (830 nm) = 37.8 mW / cm 2 , 2 minute survey

[0432] About 4.5 J / cm 2

[0433] B. Test method

[0434] 1) In vitro safety evaluation of multi-wavelength LEDs targeting retinal pigment epithelial cells

[0435] - ARPE-19 cells, which are retinal pigment epithelial cells, were cultured in a medium.

[0436] - Dispense into 12-well plates when cultured at 80% confluence

[0437] - Light irradiation was performed on the plate containing ARPE-19 cells using a multi-wavelength (680nm±10nm, 780nm±10nm, 830nm±10nm) LED light source module.

[0438] a) Exposure to light over time and cell viability was confirmed through cell viability after 24 hours (0, 0.5, 1, 2, 4, 8 minutes) (MTT assay)

[0439] b) 37.8 mW / cm 2 , 2 minutes (4.5 J / cm 2 ) after fixation with light irradiation for 0, 24, 48, and 72 hours, cell proliferation rate was confirmed through proliferation assay (MTT assay)

[0440] ⓛ MTT assay

[0441] - Retinal epithelial cells (ARPE-19) were cultured in an incubator at 5% CO2 and 37°C using DMEM (Dulbecco's Modified Eagle Medium) medium.

[0442] - Retinal epithelial cells were seeded in a 12-well plate and irradiated with a multi-wavelength LED light source after 24 hours.

[0443] - The light source is irradiated by aligning the cylindrical end of the LED to one well seeded with cells in a 12-well plate (distance from the cylinder to the cells: 17 mm).

[0444] - After culturing for 0, 24, 48, and 72 hours, remove the medium, add 50 μL of MTT solution and 100 μL of medium, and incubate for 4 hours in an incubator with light blocked.

[0445] - After removing the reactant after 4 hours, add 100 μL of DMSO and measure the absorbance at 595 nm using a spectrophotometer.

[0446] 2) NaIO3 In vivo efficacy evaluation of multi-wavelength LEDs in animal models of age-related macular degeneration

[0447] - The test group was divided into three groups as shown in Table 11.

[0448] - All groups must have at least 6 SD rats to proceed.

[0449] - NaIO3 in 6-week-old SD rats 35 mg / kg was injected into the tail vein.

[0450] - NaIO3 Tissues were removed 1, 2, 3, 4, and 7 days after injection to determine the extent of ONL reduction in the retina.

[0451] - 37.8 mW / cm in rat eyes after injection 2 , for 2 minutes (4.5 J / cm 2 ) Light irradiation in progress (5 times)

[0452] - NaIO3 Tissues were removed 7 days after injection and subsequent experiments were conducted.

[0453] Control (n=6)Normal control group (saline solution)Dry AMD 7day (n=8)NaIO3 Group 7 days after 35mg / kg injection Dry AMD+LED 7day (n=)NaIO3 Group on the 7th day of 35 mg / kg injection + 5 light irradiation sessions

[0454] ① Histological observation (see Table 12)

[0455] - For each group, experimental animals were sacrificed at each period, eye tissue was extracted, fixed in 10% formalin solution, and then infiltrated with 15% or 30% sucrose. The tissue was solidified using OCT and frozen into 10 μm sections.

[0456] -H&E staining was confirmed with a tissue microscope, and then the ONL of the retina was measured and analyzed.

[0457] - TUNEL staining was confirmed using a confocal microscope, and the number of TUNEL positive cells in the ONL of the retina was counted and analyzed.

[0458] - PKC-α was confirmed using a confocal microscope, and the number of PKC-α positive cells in the OPL (Outer plexiform layer) and INL (Inner nuclear layer) was counted and analyzed.

[0459] - After confirming rhodopsin using a confocal microscope, the intensity of rhodopsin fluorescence expression in the PR (photoreceptor layer) was analyzed using the image analysis program ImageJ (NIH).

[0460] Hematoxylin & Eosin (H&E) stain to confirm the thickness of the retinal ONL (Outer Nuclear Layer). TUNEL stain to confirm cell death in the retinal ONL. PKC-α stain to confirm biopolar cells. Rhodopsin, RPE 65 to confirm Rod photoreceptors and RPE (Retinal pigment epithelium).

[0461] D. Tests and Results

[0462] 1) In vitro safety evaluation of multi-wavelength LEDs targeting retinal pigment epithelial cells

[0463] - Measurement of cell survival rate through cell viability 24 hours after light exposure

[0464] - As shown in Figure 27, multi-wavelength LED irradiation at each time point of 0, 0.5, 1, 2, 4, and 8 minutes did not reduce the cell viability of retinal pigment epithelial cells. Therefore, it was determined that there was no cytotoxicity due to multi-wavelength LED irradiation.

[0465] - Measurement of cell proliferation rate through proliferation assay for 0, 24, 48, and 72 hours after light irradiation

[0466] - As shown in Figure 28, it was confirmed that multi-wavelength LED irradiation did not cause any problems in cell proliferation of retinal pigment epithelial cells over time.

[0467] 2) NaIO3 In vivo efficacy evaluation of multi-wavelength LEDs in animal models of age-related macular degeneration

[0468] - NaIO3 Eyes were extracted 1, 2, 3, 4, and 7 days after treatment and stained with H&E.

[0469] - As shown in Figure 29, the thickness of the entire retina and ONL were analyzed using NaIO3 Establishment of macular degeneration animal model conditions 7 days after treatment

[0470] - NaIO3 After 7 days of multi-wavelength LED treatment, each eye was removed and stained with H&E.

[0471] - The ONL (outer nuclear layer), which is composed of the nucleus of the photoreceptor cell, is a layer of the nuclei of the photoreceptor cells. Therefore, by measuring the thickness of the ONL, it was confirmed that the number of ONL photoreceptor cells decreases due to macular degeneration.

[0472] - As shown in Figure 30, the thickness of ONL in the retina was analyzed, and the macular degeneration animal model showed a significant decrease of 14.7% compared to the normal control group, and the multi-wavelength LED treatment group showed a significant increase of 12.3% compared to the macular degeneration animal model.

[0473] Table 13 shows the changes in ONL thickness in the retina due to macular degeneration and multi-wavelength LED treatment.

[0474] ONL thickness (㎛)Control (n=6)Dry AMD (n=8)Dry AMD +LED (n=8)Average91.2577.8387.38SEM9.930.991.46

[0475] - NaIO3 And 7 days after multi-wavelength LED treatment, the extracted eyes were sectioned and TUNEL assay was performed to check for apoptosis in the tissue.

[0476] - As shown in Figure 31, the TUNEL reagent is a method of fluorescently staining cells undergoing apoptosis. As a result of counting TUNEL-positive apoptotic cells in the ONL of the retina, the macular degeneration animal model showed a significant increase of 115.1% compared to the normal control group, and the multi-wavelength LED treatment group showed a significant decrease of 42.8% compared to the macular degeneration animal model. There was no significant difference between the control group and the LED treatment group.

[0477] - Table 14 shows the results of TUNEL-positive cell counting in the retina after macular degeneration and multi-wavelength LED treatment.

[0478] TUNEL-positive cells (pcs)Control (n=6)Dry AMD (n=8)Dry AMD +LED (n=8)Average155.78335.12191.52SEM7.2340.8823.06

[0479] - NaIO3 And 7 days after multi-wavelength LED treatment, the extracted eyes were sectioned and immunofluorescent staining was performed to confirm the expression of PKCα, a bipolar cell marker in the retina.

[0480] - As shown in Figure 32, bipolar cells are mainly located in the inner nuclear layer (INL) of the retina, and form synapses in both the outer plexiform layer (OPL) and the inner plexiform layer (IPL), which are the upper and lower layers of the INL. Therefore, in terms of the visual pathway, bipolar cells play an important role in transferring electrochemical signals transmitted from photoreceptor cells to the ganglion, and thus, these bipolar cells were identified.

[0481] - Counting PKCα-positive cells in the retina after PKCα immunofluorescence staining showed a significant 18.4% decrease in the macular degeneration animal model compared to the normal control group, while the multi-wavelength LED treatment group showed a significant 7% increase compared to the macular degeneration animal model. There was no significant difference between the control group and the LED treatment group.

[0482] - Table 15 shows the results of PKCα-positive cell counting in the retina by semi-degeneration and multi-wavelength LED treatment.

[0483] PKCα-positive cells (pcs)Control (n=6)Dry AMD (n=8)Dry AMD +LED (n=8)Average38.9431.7934.00SEM2.291.300.82

[0484] - NaIO3 And 7 days after multi-wavelength LED treatment, the extracted eyes were sectioned and immunofluorescence stained to confirm the expression of Rhodopsin, a marker of Rods in the PR of the retina, and RPE65, a marker of RPE.

[0485] - Through Rhodopsin, a marker of Rods, we confirmed the change in Rods, which are receptors in the retina responsible for vision and convert light entering the eye into electrical signals that can be decoded in the visual processing area of ​​the brain. We also measured the fluorescence intensity of the RPE65 marker to confirm changes in the RPE layer that absorbs light entering the eye due to macular degeneration and multi-wavelength LED.

[0486] - As shown in Figure 33, the intensity of rhodopsin fluorescence expression in the PR of the retina after immunofluorescence staining was analyzed using the image analysis program ImageJ software (NIH). As a result, the macular degeneration animal model showed a significant decrease of 78.1% compared to the normal control group, and the multi-wavelength LED treatment group showed a significant increase of 248.2% compared to the macular degeneration animal model. There was no significant difference between the control group and the LED treatment group.

[0487] - After immunofluorescence staining, the fluorescence expression intensity of RPE65, a marker of the RPE layer of the retina, was analyzed using the image analysis program ImageJ software (NIH). As a result, the macular degeneration animal model showed a significant decrease of 34.2% compared to the normal control group, and the multi-wavelength LED treatment group showed a significant increase of 38.3% compared to the macular degeneration animal model. There was no significant difference between the control group and the LED treatment group.

[0488] - Table 16 is a table showing the results of analysis of Rhodopsin fluorescence expression intensity by macular degeneration and multi-wavelength LED treatment in PR, and Table 17 is a table showing the results of analysis of RPE65 fluorescence expression intensity by macular degeneration and multi-wavelength LED treatment.

[0489] Rhodopsin fluorecent intensityControl (n=6)Dry AMD (n=8)Dry AMD +LED (n=8)Average14.093.0910.76SEM2.270.471.65

[0490] RPE65 fluorecent intensityControl (n=6)Dry AMD (n=8)Dry AMD +LED (n=8)Average2.471.622.25SEM0.250.070.15

[0491] A. Test Results Conclusion

[0492] 1) In this study, retinal pigment epithelial cells were used to evaluate the safety of multi-wavelength LEDs that simultaneously irradiate three wavelengths of 680 nm, 780 nm, and 830 nm. It was confirmed that treatment of retinal pigment epithelial cells with multi-wavelength LEDs did not reduce cell viability or cell proliferation over time depending on energy.

[0493] 2) To establish an animal model of macular degeneration, mice were treated with 35 mg / kg of sodium iodine, and the thickness of the entire retina and ONL was analyzed. The most significant damage was confirmed on the 7th day of injection, establishing an animal model of dry macular degeneration.

[0494] 3) When multi-wavelength LEDs were applied to an animal model of macular degeneration, the thickness of the ONL in the retina significantly increased by 12.3% compared to the macular degeneration model.

[0495] 4) The results of the TUNEL assay, which can identify apoptotic cells, showed that multi-wavelength LED significantly reduced the number of apoptotic cells by 42.8% compared to the macular degeneration animal model.

[0496] 5) Analysis of the number of cells expressing PKCα, a marker of bipolar cells in the retina, showed that multi-wavelength LED significantly increased the number of PKCα-positive cells by 7% compared to an animal model of macular degeneration.

[0497] 6) As a result of analyzing the fluorescence expression intensity of Rhodopsin, a marker of Rods in the PR of the retina, the multi-wavelength LED significantly increased the fluorescence expression intensity of Rhodopsin by 248.2% compared to the animal model of macular degeneration.

[0498] 7) As a result of analyzing the fluorescence expression intensity of RPE65, a marker of the RPE layer of the retina, the multi-wavelength LED significantly increased the fluorescence expression intensity of RPE65 by 38.3% compared to the macular degeneration animal model.

[0499] 8) Based on the results of this test, it was determined that multi-wavelength LEDs are not toxic to retinal pigment epithelial cells and significantly restored the reduction in bipolar cells, which play an important role in the visual pathway, and damage to the Rods and RPE layers, which are receptors for visual information, in an animal model that induced macular degeneration, thereby significantly restoring the thickness reduction and cell death of the retinal ONL.

[0500] 9) As a result of this test, when the wavelength and light intensity conditions of the test equipment described above are applied to the user's eyes for the treatment or alleviation of macular degeneration / macular edema, it is judged that not only will the user's cornea not be damaged, as in Test Example 1, but the user's cornea can also be improved to a better condition.

[0501] -Test Example 3 (Macular Edema Test)

[0502] A. Test conditions

[0503] 1) In vivo test animals:

[0504] a) Test animal strain: SD rat

[0505] B) Test animal sex / quantity: Male / 18 animals

[0506] D) Test animal weight / age: 150~200 g / 6 weeks old

[0507] 2) Induction of macular edema

[0508] - Physiological saline containing 55 mg / kg of streptozotocin (STZ)

[0509] 3) Test staining reagent

[0510] a) H&E stain reagent

[0511] - Hematoxylin, Eosin

[0512] - EtoH, Xylene

[0513] 4) Testing equipment

[0514] Considering that this is a test to verify the effectiveness of the eye disease treatment system according to the present invention, the test equipment was configured as shown in Fig. 16.

[0515] a) Wavelength conditions

[0516] LEDs of 680 nm, 780 nm, and 830 nm, where each wavelength can be varied by ±10 nm.

[0517] b) Light intensity (irradiation energy is the average light output of each LED)

[0518] 12.3 mW (680 nm) + 14.9 mW (780 nm) + 10.6 mW (830 nm) = 37.8 mW / cm 2 , 2 minute survey

[0519] About 4.5 J / cm 2

[0520] B. Test method

[0521] - Establishment of an animal model of retinopathy (macular edema; ME) by inducing diabetes

[0522] - To induce diabetic retinopathy (macular edema) animal model, STZ was administered subcutaneously once at a concentration of 55 mg / kg.

[0523] - Starting the day after administration, light is irradiated to the entire eye area three times using a multi-wavelength (680nm, 780nm, 830nm) LED light source module.

[0524] - The test group was divided into three groups as shown in the table below (see Table 18).

[0525] - Animals were raised for 30 days from the date of administration, and after the experiment, the experimental animals in each group were sacrificed and eye tissues were extracted. After fixation in 10% formalin solution, the tissues were infiltrated using 15% and 30% sucrose. They were solidified using OCT and frozen into 10 μm sections.

[0526] - H&E staining was performed to measure and analyze the ONL (Outer Nuclear Layer) of the retina.

[0527] Control (n=2) Normal control group (saline solution) STZ (n=8) Group in which macular edema was induced with streptozotocin STZ+LED (n=8) Group in which macular edema was induced and then LED irradiated

[0528] D. Tests and Results

[0529] 1) Creation and verification of an animal model of diabetic retinopathy (macular edema)

[0530] - To create an animal model of diabetic retinopathy (macular edema), STZ, which induces diabetes, was administered intraperitoneally once at a dose of 55 mg / kg.

[0531] - LED irradiation was performed three times a week starting the day after STZ administration (2 minutes per session, 4.5 J / cm) 2 )

[0532] - As shown in Figure 34, one week after STZ administration, blood sugar levels were measured, and compared to normal (100-200 mg / dL), only animals with blood sugar levels of 600 mg / dL or higher (indicated as High on a blood sugar meter) were selected and divided into diabetic retinopathy (macular edema) and LED irradiation groups.

[0533] - The animals were reared for 30 days and weight changes were observed at 3-4 day intervals.

[0534] - As shown in Figure 35, significant changes in body weight were observed between the normal control group and the STZ and STZ+LED groups from the 7th day.

[0535] 2) In vivo efficacy evaluation of multi-wavelength LED in an animal model of diabetic retinopathy (macular edema)

[0536] - To create an animal model of diabetic retinopathy (macular edema), STZ, which induces diabetes, was administered and the animals were raised for 30 days, after which they were sacrificed and the retinas of the extracted eyes were stained with H&E.

[0537] - As illustrated in Figure 36, the ONL (outer nuclear layer), composed of the nucleus of photoreceptor cells, is a structure in which the nuclei of photoreceptor cells form multiple layers, and its thickness decreases due to the decrease in photoreceptor cells when the retina is damaged. Therefore, in this test, the thickness of the ONL was measured and it was confirmed that the number of ONL photoreceptor cells decreased due to diabetic retinopathy (macular edema).

[0538] - The thickness of ONL was analyzed by analyzing the retinal H&E stained images and measuring the changes caused by multi-wavelength LED.

[0539] - ONL thickness analysis results showed that the normal control group had an average thickness of 75.4 ± 1.7 μm, while the macular edema animal model had an average thickness of 67.3 ± 2.1 μm, a significant 10.7% decrease in ONL thickness.

[0540] - However, the ONL thickness of the multi-wavelength LED treatment group was measured at an average of 74.7 ± 2.4 μm, which was a significant increase of 11% compared to the ONL thickness of the diabetic retinopathy (macular edema) animal model.

[0541] Table 19 shows the ONL thickness evaluation by multi-wavelength LED treatment in an animal model of diabetic retinopathy (macular edema).

[0542] Corneal detach densityControlME (macular edema)ME +LEDAverage75.4567.3474.72SEM1.652.132.37

[0543] A. Test Results Conclusion

[0544] 1) In this study, a histological evaluation of a multi-wavelength LED that simultaneously irradiates three wavelengths of 680 nm, 780 nm, and 830 nm was performed using H&E staining. When treated in an animal model of diabetic retinopathy (macular edema), the change in the thickness of ONL in the retina was confirmed. It was confirmed that the ONL thickness was significantly reduced by 10.7% in the diabetic retinopathy (macular edema) animal model compared to the normal control group. There was no significant difference between the control group and the LED treatment group.

[0545] 2) On the other hand, in the group exposed to multi-wavelength LED, it was confirmed that ONL thickness increased significantly by 11% compared to the animal model of diabetic retinopathy (macular edema).

[0546] 3) Based on the results of this test, it was determined that multi-wavelength LED significantly increased the thickness of the retinal ONL in an animal model of diabetic retinopathy (macular edema), thereby restoring reduced vision.

[0547] Meanwhile, the wavelength and intensity of the light irradiated by the test device illustrated in Fig. 16 are as shown in Table 20.

[0548] Classification EDC680 DEDC780 DEDC830 NTotal Sample N# Wavelength (nm) Irradiance (mW / cm2) Wavelength (nm) Irradiance (mW / cm2) Wavelength (nm) Irradiance (mW / cm2) Irradiance (mW / cm2) 167812.61877214.68582210.28137.584267711.70877214.57982310.49836.785367712.55877214 .61682210.82337.997467712.56877215.07282210.46138.101567812.16477215.23682310.74738.147667712.24677315.09282210.81438.152average-12.3103-14.88-10.60437.7943

[0549] And through the test results as above, the present invention can be summarized as follows.

[0550] First, the system for treating eye diseases according to the present invention includes a light care device described with reference to FIGS. 1 to 14, as well as a light module (100) that generates three or more lights with different wavelengths and irradiates the light to the user's eyes, and is characterized in that the three or more lights include lights with a second wavelength of 680 nm ± 10 nm, a third wavelength of 780 nm ± 10 nm, and a fourth wavelength of 830 nm ± 10 nm.

[0551] Here, the sum of the irradiation intensities of the light of the above 2 to 4 wavelengths is 35 to 40 mW / cm 2 It is desirable that the sum of the irradiation intensities of the light of the above 2 to 4 wavelengths is 37.8 mW / cm 2 It is more desirable that

[0552] In addition, the average value of the light irradiation intensity of the second wavelength light is 12.3 mW / cm 2 , and the average value of the light irradiation intensity of the third wavelength light is 14.9 mW / cm 2 , and the average value of the light irradiation intensity of the fourth wavelength light is 10.6 mW / cm 2 It is desirable that.

[0553] In addition, the light of the above 2 to 4 wavelengths has an energy of 5.0 J / cm irradiated for 2 minutes. 2 It can be investigated in smaller detail.

[0554] And the light of the above 2 to 4 wavelengths can be irradiated to the user's eyes simultaneously.

[0555] The above three or more lights may additionally include light having a first wavelength of 590±10 nm.

[0556] The system for treating eye diseases according to the present invention having the above configuration can be used for treating or alleviating symptoms of at least one eye disease among dry eye, macular edema, and macular degeneration.

[0557] Meanwhile, in the case where the system for treating eye diseases according to the present invention is used for the care / treatment / alleviation of symptoms of dry eye, considering that the irradiated light is irradiated to the cornea, the distance between the objective lens of the optical system constituting the optical module (100) and the cornea is preferably 1.5 cm to 2.0 cm, and more preferably 1.7 cm.

[0558] For example, when the above-described eye disease treatment system has a structure similar to glasses as illustrated in FIGS. 1 to 14, the distance between the objective lens of the optical module (100) and the cornea in a worn state is preferably 1.5 cm to 2.0 cm, and more preferably 1.7 cm.

[0559] In addition, when the system for treating eye diseases according to the present invention is used for the care / treatment / alleviation of symptoms of macular degeneration and / or macular edema, the irradiated light is preferably 3.9 cm to 4.4 cm, and more preferably 4.1 cm, considering that the irradiated light is irradiated to the retina.

[0560] For example, when the above-described eye disease treatment system has a structure similar to glasses as illustrated in FIGS. 1 to 14, the distance between the objective lens of the optical module (100) and the cornea in a worn state is preferably 3.9 cm to 4.4 cm, and more preferably 4.1 cm.

[0561] For reference, the average distance between the cornea and the retina is 2.4 cm.

[0562] Meanwhile, the treatment system for treating eye diseases, the method for treating eye diseases, and the optical module used therein according to the present invention have been described as an example of being used for the purpose of treating eye diseases, but of course, they can also be used as an eye disease treatment system that irradiates light to the user's eyes to provide optical stimulation to retinal cells to maintain or strengthen the activity state of retinal cells.

[0563] That is, it goes without saying that the treatment system for treating eye diseases according to the present invention, in addition to a medical device for treating eye diseases, can also be used as a health supplementary device that can maintain or improve eye health.

[0564] If the present invention is used as a health supplementary device for eye health rather than for the treatment of eye diseases, it can be configured in various ways, such as being configured to irradiate a single light having a wavelength of 590±10 nm instead of being configured to irradiate multiple lights.

[0565]

[0566] Although the preferred embodiments of the present invention have been described above by way of example, the scope of the present invention is not limited to these specific embodiments, and may be appropriately modified within the scope set forth in the claims.

Claims

1. A light module (100) that generates care light is installed, and a main body module (10) that covers the user's eyes so that the light of the light module (100) is irradiated to the user's eyes; A system for treating eye diseases, characterized in that it includes a wearable part (20) that is coupled to the main body module (10) and extends to the side of the user's head and is worn by the user.

2. In claim 1, The above optical module (100) is An LED module (100) including an LED substrate (112) on which one or more LED elements (111) are installed; First, a tube (120) to which the LED module (100) is coupled; One or more lenses (141) installed in the above-mentioned tube (120) and emitting light generated by the LED element (111); A system for treating eye diseases, characterized in that it comprises a diffusion member (142) that is coupled to the above-mentioned optical tube (120) to diffuse light; and a fixing member (130) that is coupled to the above-mentioned optical tube (120) to fix the lens (141) and the diffusion member (142).

3. In claim 1, The above optical module (100) is A tube (120) having a hollow cylinder structure; An LED module (110) including an LED substrate (112) that is connected to one end of the above-mentioned tube (120) and has a through-hole (113) corresponding to the hollow of the above-mentioned tube (120) formed therein and on which a plurality of LED elements (111) are installed along the circumferential direction; A reflective member (151) that is coupled to one end of the above-mentioned tube (120) and reflects light generated from the plurality of LED elements (111) toward the hollow portion of the above-mentioned tube (120); A spherical lens (152) installed in the above-mentioned tube (120) and converging the light reflected by the reflective member (151); A system for treating eye diseases, characterized in that it includes a guide lens (153) that guides light passing through the spherical lens (152) into a preset area.

4. In any one of claims 1 to 3, The above LED element (111) is A first LED element that irradiates light in the blue wavelength range; A second LED element that irradiates light in the green wavelength range; A third LED element that irradiates light in the red wavelength range; A fourth LED element that irradiates light in the ultraviolet wavelength range; A system for treating eye diseases, characterized in that it includes at least one of the fifth LED elements that irradiate light in the infrared wavelength range.

5. A tube (120) having a hollow cylinder structure; An LED module (110) including an LED substrate (112) that is connected to one end of the above-mentioned tube (120) and has a through-hole (113) corresponding to the hollow of the above-mentioned tube (120) formed therein and on which a plurality of LED elements (111) are installed along the circumferential direction; A reflective member (151) that is coupled to one end of the above-mentioned tube (120) and reflects light generated from the plurality of LED elements (111) toward the hollow portion of the above-mentioned tube (120); A spherical lens (152) installed in the above-mentioned tube (120) and converging the light reflected by the reflective member (151); An optical module for eye care, characterized in that it includes a guide lens (153) that guides light passing through the spherical lens (152) into a preset area.

6. A tube (120) having a hollow cylinder structure; An LED module (110) including an LED substrate (112) that is connected to one end of the above-mentioned tube (120) and has a through-hole (113) corresponding to the hollow of the above-mentioned tube (120) formed therein and on which a plurality of LED elements (111) are installed along the circumferential direction; A reflective member (151) that is coupled to one end of the above-mentioned tube (120) and reflects light generated from the plurality of LED elements (111) toward the hollow portion of the above-mentioned tube (120); A spherical lens (152) installed in the above-mentioned tube (120) and converging the light reflected by the reflective member (151); An optical module for eye care, characterized in that it includes a guide lens (153) that guides light passing through the spherical lens (152) into a preset area.

7. In claim 5 or claim 6, The above LED element (111) is A first LED element that irradiates light in the blue wavelength range; A second LED element that irradiates light in the green wavelength range; A third LED element that irradiates light in the red wavelength range; A fourth LED element that irradiates light in the ultraviolet wavelength range; An optical module for eye care, characterized by including at least one of the fifth LED elements that irradiate light in the infrared wavelength range.

8. A system for treating eye diseases that generates three or more lights with different wavelengths and irradiates the light to the user's eyes. A system for treating an eye disease according to any one of claims 1 to 3, A system for treating eye diseases, characterized in that the three or more lights include lights having a second wavelength of 680 nm ± 10 nm, a third wavelength of 780 nm ± 10 nm, and a fourth wavelength of 830 nm ± 10 nm.

9. In claim 8, The sum of the irradiation intensities of the above 2 to 4 wavelengths of light is 35 to 40 mW / cm 2 A system for treating eye diseases, characterized by:

10. In claim 9, The sum of the irradiation intensities of the light of the above 2 to 4 wavelengths is 37.8 mW / cm 2 A system for treating eye diseases, characterized by:

11. In claim 8, The average value of the light irradiation intensity of the above second wavelength light is 12.3 mW / cm 2 and, The average value of the light irradiation intensity of the above third wavelength light is 14.9 mW / cm 2 and, The average value of the light intensity of the above fourth wavelength light is 10.6 mW / cm 2 A system for treating eye diseases, characterized by:

12. In claim 8, A system for treating eye diseases, characterized in that the light of the above 2 to 4 wavelengths is simultaneously irradiated to the user's eyes.

13. In claim 8, The light of the above 2 to 4 wavelengths has an energy of 5.0 J / cm irradiated for 2 minutes. 2 A system for treating eye diseases characterized by being investigated in a smaller scale.

14. In claim 8, A system for treating eye diseases, characterized in that the three or more lights above additionally include light with a first wavelength of 590 nm±10.

15. In claim 8, A system for treating eye diseases, characterized in that it is used for treating or alleviating symptoms of at least one eye disease among dry eye, macular edema, and macular degeneration.

16. Includes an optical module (100) that generates three or more lights with different wavelengths and irradiates light to the user's eyes. A system for treating eye diseases, characterized in that the three or more lights include lights having a second wavelength of 680 nm ± 10 nm, a third wavelength of 780 nm ± 10 nm, and a fourth wavelength of 830 nm ± 10 nm.

17. In claim 16, The sum of the irradiation intensities of the above 2 to 4 wavelengths of light is 35 to 40 mW / cm 2 A system for treating eye diseases, characterized by:

18. In claim 17, The sum of the irradiation intensities of the light of the above 2 to 4 wavelengths is 37.8 mW / cm 2 A system for treating eye diseases, characterized by:

19. In claim 16, The average value of the light irradiation intensity of the above second wavelength light is 12.3 mW / cm 2 and, The average value of the light irradiation intensity of the above third wavelength light is 14.9 mW / cm 2 and, The average value of the light intensity of the above fourth wavelength light is 10.6 mW / cm 2 A system for treating eye diseases, characterized by:

20. In any one of claims 16 to 19, A system for treating eye diseases, characterized in that the light of the above 2 to 4 wavelengths is simultaneously irradiated to the user's eyes.

21. In any one of claims 16 to 19, The light of the above 2 to 4 wavelengths has an energy of 5.0 J / cm irradiated for 2 minutes. 2 A system for treating eye diseases characterized by being investigated in a smaller scale.

22. In any one of claims 16 to 19, A system for treating eye diseases, characterized in that the three or more lights further include light having a first wavelength of 590 nm.

23. In any one of claims 16 to 19, A system for treating eye diseases, characterized in that it is used for treating or alleviating symptoms of at least one eye disease among dry eye, macular edema, and macular degeneration.

24. In claim 1, A system for treating eye diseases, characterized in that it includes a camera unit (300) installed in the main body module (10) and acquires an image of the user's eye to track whether the light irradiated by the optical module (100) is stably irradiated to the user's eye.

25. In claim 24, The above camera part (300) is A system for treating an eye disease, characterized by including a camera that recognizes at least one of infrared and visible light.

Images